LA JOLLA PHARMACEUTICAL CO Form 8-K May 07, 2004

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

## WASHINGTON, DC 20549

# FORM 8-K

#### **CURRENT REPORT**

## Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 6, 2004

## LA JOLLA PHARMACEUTICAL COMPANY

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation) 0-24274 (Commission File Number) 33-0361285 (IRS Employer Identification No.)

6455 Nancy Ridge Drive San Diego, California 92121 (Address of Principal Executive Offices, including Zip Code)

(858) 452-6600 (Registrant s telephone number, including area code)

# TABLE OF CONTENTS

Item 12. Results of Operations and Financial Condition. SIGNATURES EXHIBIT INDEX EXHIBIT 99.1

#### Item 12. Results of Operations and Financial Condition.

In a press release on May 6, 2004, La Jolla Pharmaceutical Company announced and commented on its financial results for its first quarter ended March 31, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein. The press release is being furnished to the Securities and Exchange Commission under Item 12 Results of Operations and Financial Condition.

The information in this Form 8-K and the exhibit attached hereto and incorporated herein shall not be deemed filed for purposes of the Securities Exchange Act of 1934, as amended (the Exchange Act ), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

# SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: May 6, 2004

# LA JOLLA PHARMACEUTICAL COMPANY

By: /s/ Gail A. Sloan Gail A. Sloan Vice President Finance, Controller and Secretary

# EXHIBIT INDEX

# ExhibitNumberDescription of Exhibit

99.1 Press Release (furnished pursuant to Item 12 of Form 8-K)